Patient case: 45-year-old female with Meningioma. Genetic variant: NF2 (K322), AKT1(E17K). Other conditions: None.

Clinical trial: Auditory Brainstem Implant (ABI) in Children With No Cochleae or Auditory Nerves

Summary: This study is a feasibility study of the Nucleus 24 ABI in children without NF2. It will be conducted as a repeated-measures, single subject experiment in order to accommodate the known variability in cochlear implant clinical results. Data obtained in the course of this study will be compared with the existing published outcome data from children with normal hearing and with cochlear implants (CIs). These comparisons may provide additional useful information about the progress of ABI subjects' performance over time. Also, this may allow the results of the current study to be utilized to design future pivotal studies of the device in the pediatric population.

Detailed description: The purpose of this study is to evaluate the clinical safety and efficacy of the Nucleus™ 24 Auditory Brainstem Implant (ABI) in pediatric patients who do not have Neurofibromatosis Type 2 (NF2); specifically, children with total hearing loss due to severe cochlear anomalies, cochlear nerve disorders or failed cochlear implantation. These conditions can include: developmental or acquired cochlear nerve deficiency (CND), cochlear aplasia, post-meningitis cochlear ossification, or cochlear malformation. This study proposes to implant up to 10 pre-linguistic young children (18 mos to 5 yrs. of age) and up to 10 post-linguistic children (<21 yrs of age) with the Nucleus 24 Multichannel ABI in an attempt to demonstrate safety of the surgical procedure and device stimulation and the potential for auditory benefit beyond that experienced with a CI. These children would not qualify for the Nucleus ABI device, as their etiology is not an approved indication such as neurofibromatosis Type 2(NF2). Further, these children do not benefit from conventional hearing aids or cochlear implants.
  Two groups of children will be included: Group 1 will include prelingiustic deaf children ages 18 months - 5 years and Group 2 will include postlinguistic deaf children < 21 years of age. Post-operative evaluations will be conducted at the initial activation and at 1, 3, 6, 12, 18, 24, 30, and 36-month intervals post-activation in order to demonstrate the emergence of open-set speech perception abilities prior to study cessation. Experience in the CI literature has shown that a minimum of 2 years of device usage is required for children with pre-lingual hearing impairment to develop some open-set speech perception abilities. While Group 2 is post-linguistic and some may have had significant hearing prior to becoming deaf, the same time intervals will be used for consistency. Blinding or masking procedures are not included in the design, as the presence/absence of a brainstem implant cannot be easily concealed from the device recipients and/or clinical investigators.

Eligibility: Inclusion Criteria:
  Group 1: Prelinguistic hearing loss (birth-5 years; age at implantation of ABI 18 months-5 years)
  • Pre-linguistic hearing loss (birth-5 yrs.; age at ABI 18 months-5yrs) with both:
  -  MRI +/- CT evidence of one of the following:
  -  Cochlear nerve deficiency
  -  Cochlear aplasia or severe hypoplasia
  -  Severe inner ear malformation
  -  Post-meningitis ossification
  -  When a cochlea is present or patent, lack of significant benefit from CI despite consistent use (>6 mo.)
  -  No or limited speech perception ability (limited to pattern perception on closed set testing materials using the CI)
  -  Lack of progress in auditory skills development
  Group 2: Post-linguistic hearing loss (<21 yrs. of age)
  -  Post-linguistic hearing loss (<21 yrs. of age) with:
  -  Loss or lack of benefit from appropriate CI without the possibility for revision or contralateral implantation. Examples might include:
  -  Post-meningitis ossification
  -  Bilateral temporal bone fractures with cochlear nerve avulsion
  -  Failed revision CI without benefit
  -  Previously developed open set speech perception and auditory-oral language skills
  -  No medical contraindications
  -  Willing to receive the appropriate meningitis vaccinations
  -  No or limited cognitive/developmental delays.
  -  Strong family support
  -  Reasonable expectations from parents/guardians including a thorough understanding:
  -  of potential benefits and limitations of ABI
  -  of parental role in rehabilitation
  -  that the child may not develop spoken language as a primary communication mode or even sufficient spoken language to make significant academic progress in an aural/oral environment
  -  Involvement in a rehabilitation program that emphasizes development of auditory skills with or without the use of supplementary visual communication.
  -  Able to comply with study requirements including travel to investigation sites.
  -  Informed consent for the procedure from the child's parents/legal guardian.
  Exclusion Criteria:
  For both Groups 1 and 2:
  -  Pre- or post-linguistic child currently making significant progress with CI Even for the very young children (18 months of age with 6 months of use), nearly all children with a good auditory signal from their CI will show evidence of improvement in these metrics over time.
  -  MRI evidence of one of the following:
  -  normal cochlea and cochlear nerves or NF2
  -  brainstem or cortical anomaly that makes implantation unfeasible
  -  Clear surgical reason for poor CI performance that can be remediated with revision CI or contralateral surgery rather than ABI.
  -  Intractable seizures or progressive, deteriorating neurological disorder
  -  Patients with evidence of Chiari malformation, hydrocephalus, spina bifid a
  -  Patients with any foreseeable need for a future MRI scan
  -  Unable to participate in behavioral testing and mapping with their CI. If this appears to be an age effect, ABI will be delayed until we can be assured that the child will be able to participate, as reliable objective measures of mapping are currently not available for mapping these devices.
  -  Unable to tolerate general anesthesia (cardiac, pulmonary, bleeding diathesis, etc.).
  -  Need for brainstem irradiation
  -  Unrealistic expectations on the part of the subject/family regarding the possible benefits, risks and limitations inherent to the procedure and ABI device.
  -  Unwilling to sign the informed consent.
  -  Unwilling to make necessary follow-up appointments.

Relevance to patient case: not relevant